Corporación América Airports S.A. (CAAP)
NYSE: CAAP · Real-Time Price · USD
19.91
+0.06 (0.30%)
Jul 31, 2025, 4:00 PM - Market closed
CTI BioPharma Stock Forecast
Stock Price Forecast
The 2 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $24.35, which forecasts a 22.30% increase in the stock price over the next year. The lowest target is $24 and the highest is $24.7.
Price Target: $24.35 (+22.30%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 2, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 1 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $23 → $24 | Buy | Maintains | $23 → $24 | +20.54% | Jul 2, 2025 |
| B of A Securities | B of A Securities | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +24.06% | May 22, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $23 | Buy | Initiates | $23 | +13.01% | Mar 14, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $21 → $22 | Strong Buy | Maintains | $21 → $22 | +7.99% | Jun 3, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $21 | Hold → Strong Buy | Upgrades | $21 | +5.47% | Jan 9, 2024 |
Financial Forecast
Revenue This Year
1.86B
from 1.84B
Increased by 0.91%
Revenue Next Year
2.10B
from 1.86B
Increased by 12.63%
EPS This Year
1.59
from 1.75
Decreased by -9.26%
EPS Next Year
2.23
from 1.59
Increased by 40.55%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 2.1B | 2.6B | 3.0B | |
| Avg | 1.9B | 2.1B | 2.2B | |
| Low | 1.7B | 1.8B | 1.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 11.5% | 37.2% | 41.7% | |
| Avg | 0.9% | 12.6% | 6.6% | |
| Low | -9.0% | -3.1% | -9.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.97 | 3.06 | 4.23 |
| Avg | 1.59 | 2.23 | 2.69 |
| Low | 0.99 | 1.16 | 1.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 12.8% | 93.0% | 89.7% |
| Avg | -9.3% | 40.5% | 20.6% |
| Low | -43.4% | -27.2% | -32.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.